ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example

• DOI: 10.1016/j.vaccine.2019.07.039
• Publication Date: 2019-11-02T05:49:37Z
• Authors: Hanne-Dorthe Emborg; Johnny Kahlert; Toon Braeye; Jorgen Bauwens; Kaatje Bollaerts; Giorgia Danieli; Talita Duarte-Salles; Steffen Glismann; Consuelo Huerta-A...; Simon de Lusignan; Elisa Martín-Merino; Chris McGee; Ana Correa; Lara Tramontan; Daniel Weibel; Miriam Sturkenboom
• Keywords: Pertussis vaccine; Cumulative incidence

The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test system for rapid benefit-risk (B/R) monitoring vaccines, using existing healthcare databases Europe. objective this paper was assess the feasibility electronic estimate dose-specific acellular pertussis (aP) whole cell (wP) vaccine coverage. Seven four European countries (Denmark (n = 2), UK Spain 2) Italy 1)) participated study. Children were included from birth followed up age six years. Vaccination exposure obtained classified by type (aP or wP), dose 1, 2 3. Coverage estimated period prevalence. For 2006 cohort, two estimation methods coverage, prevalence cumulative incidence compared each database. majority 2,575,576 children had been vaccinated at country-specific recommended ages. Overall, 3 coverage 88–97% Denmark (birth cohorts 2003 2014), 96–100% (2003–2014), 95–98% (2004–2014) 94% (2006–2007). per cohort differed 1–6% with national estimates, our estimates mostly higher. 0–2% no consistent over- underestimation. In Italy, 3% lower estimates. Except which generated same results, coverages consistently 1–10% than This study showed that it possible provide immunisation included, comparable